In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor-alpha pathway.
D051722:ADAM Proteins; D000072198:ADAM17 Protein; D027322:Amino Acid Transport System X-AG / Q000378:metabolism; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001253:Astrocytes / Q000166:cytology / Q000378:metabolism; D001692:Biological Transport / Q000502:physiology; D002545:Brain Ischemia / Q000378:metabolism*; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D016923:Cell Death / Q000502:physiology; D002478:Cells, Cultured; D018920:Coculture Techniques; D004791:Enzyme Inhibitors / Q000494:pharmacology; D027342:Excitatory Amino Acid Transporter 2; D050580:Excitatory Amino Acid Transporter 3; D005947:Glucose / Q000378:metabolism; D050491:Glutamate Plasma Membrane Transport Proteins; D018698:Glutamic Acid / Q000378:metabolism* / Q000493:pharmacokinetics; D006877:Hydroxamic Acids / Q000494:pharmacology; D019194:Ischemic Preconditioning; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000502:physiology*; D027981:Symporters / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000494:pharmacology; D015854:Up-Regulation
D027322:Amino Acid Transport System X-AG; D000906:Antibodies; C108282:BB 3103; D004791:Enzyme Inhibitors; D027342:Excitatory Amino Acid Transporter 2; D050580:Excitatory Amino Acid Transporter 3; D050491:Glutamate Plasma Membrane Transport Proteins; D006877:Hydroxamic Acids; C493398:Slc1a1 protein, rat; C493395:Slc1a2 protein, rat; D027981:Symporters; D014409:Tumor Necrosis Factor-alpha; D018698:Glutamic Acid; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases; D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000072198:ADAM17 Protein; C000606464:Adam17 protein, rat; D005947:Glucose